|
 |
Intended
Audiences:
In Conversation will be pre-recorded
and available at www.cos.ca, the Web Portal of the
Canadian Oncology Societies and promoted to COS members.
In addition to medical specialists, this program will
be available to the general public.
Objective:
The program will provide an overview
of topics of significant interest arising at the 2002
San Antonio Breast Cancer Conference.
Specific goals:
Inform participants of the results
of the ATAC trial (Arimidex, Tamoxifen, Alone or in
Combination) in postmenopausal women with early breast
cancer. Updating the efficacy results based on a median
follow-up of 47 months. (note: Abstract 13)
Provide background and understanding of the NCIC
CTG MA.5 trial: A randomized trial comparing CEF to
CMF in premenopausal women with node positive breast
cancer. (note: Abstract 17)
Review the data on dose-dense chemotherapy as a
predictor of superior treatment over conventional
scheduling (CS) and equivalence of sequential (SC)
vs. combination adjuvant chemotherapy (CC) for node
positive breast cancer. (note: Abstract 15). |
